Global Thrombosis Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Thrombosis Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Thrombosis drugs can help thin the blood and help dissolve blood clots. It can also slow down the formation of blood clots and help treat thrombotic diseases.

Market Overview:

The latest research study on the global Thrombosis Drugs market finds that the global Thrombosis Drugs market reached a value of USD 40717.14 million in 2022. It’s expected that the market will achieve USD 70149.43 million by 2028, exhibiting a CAGR of 9.49% during the forecast period.

Influence of COVID-19 Outbreak on Thrombosis Drugs Industry Development

Due to the global outbreak of COVID-19, many countries have adopted strict lockdown measures, and many companies have adopted home office work. For the thrombosis drug industry, COVID-19 has affected the supply chain and industrial chain to a certain extent. COVID-19 may have affected the supply of upstream raw materials. At the same time, working from home and many pharmaceutical industries have shifted their research focus to the treatment of COVID-19, resulting in a shortage of professionals in the thrombosis drug industry. In addition, because the virus may spread through the logistics and transportation links, the inspection of logistics is stricter, which slows down the logistics and affects the delivery time and production cycle of thrombosis drugs.
Due to the COVID-19 lockdown measures, people have reduced the number of outings. Sedentary and lack of exercise are particularly noticeable during the COVID-19 lockdown. When a person accumulates blood during periods of inactivity, deep vein thrombosis can form and thicken into a blood clot. It is more likely to occur in the lower part of the body, but it may also occur in the arms or other areas. In severe cases, it may even form a pulmonary embolism. Therefore, during the COVID-19 blockade, people need to pay more attention to exercise at home, otherwise the risk of thrombosis may increase.

Drivers

Thrombosis is an abnormal blood clot in an artery or vein. Thrombosis drugs are used to prevent or treat blood clots that can cause different thrombotic events. The North American market occupies an important position in the thrombosis drug industry.

First of all, North America has a developed economy and attracts immigrants from all over the world. At the same time, the population of North America is aging. Coupled with the fast-paced lifestyle and eating habits in North America, the number of cardiovascular diseases and obesity in North America has increased rapidly. These diseases increase the risk of thrombosis, which promotes the development of the thrombosis drug industry in North America.

In addition, North America is the most economically and technologically developed region, with high income and consumption levels of residents. Coupled with the health care system and complete infrastructure, it is conducive to reimbursement of various thrombosis expenses and promotes the North American market. At the same time, the North American region has always attracted technical personnel from various industries, so that the region has an excellent talent pool to support the development of the industry. It is expected that the thrombosis drug industry in North America will continue to develop.

Region Overview:

Europe had the highest growth rate of all regions.

Company Overview:

Bayer AG is one of the major players operating in the Thrombosis Drugs market, holding a share of 16.21% in 2021.

Bayer AG manufactures products that include aspirin, antibiotics, anti-infectives, cardiovascular, oncology, central nervous system drugs, over-the-counter medications, diagnostics, and animal health products, as well as crop protection products, plastics, and polyurethanes.

Bristol-Myers Squibb Company is a global biopharmaceutical company. Bristol Myers Squibb focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.

Segmentation Overview:

Among different product types, Factor Xa Inhibitor segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Deep Vein Thrombosis segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Thrombosis Drugs market covered in Chapter 3:

Daiichi Sankyo
Aspen Pharmacare Holdings Limited
Boehringer Ingelheim GmbH
Sanofi SA
LEO Pharma
Johnson & Johnson
Bayer AG
Bristol-Myers Squibb
Chiesi
ANGDE
AstraZeneca PLC
Pfizer Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Thrombosis Drugs market from 2018 to 2029 is primarily split into:

Factor Xa Inhibitor
Low Molecular Weight Heparin
P2Y12 Platelet Inhibitor
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Thrombosis Drugs market from 2018 to 2029 covers:

Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)